BCR and cancer: In the IRIS trial (the study that allowed imatinib to enter into the clinical routine as a “magic bullet against cancer”), RQ-PCR showed that the reduction of the BCR-ABL1/ABL1 ratio of at least 3 logarithms by 18 months represented an added value to the complete cytogenetic response (CCyR) in terms of long-term survival prediction (23).